Edwards Lifesciences Corporation
EW · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -3.18 | -5.31 | -4.83 | -0.32 |
| FCF Yield | 1.14% | 0.52% | 0.53% | -0.41% |
| EV / EBITDA | 112.20 | 108.29 | 85.22 | 85.42 |
| Quality | ||||
| ROIC | 3.05% | 2.99% | 2.84% | 2.39% |
| Gross Margin | 77.88% | 77.64% | 78.65% | 78.91% |
| Cash Conversion Ratio | 1.98 | 0.88 | 0.79 | -0.33 |
| Growth | ||||
| Revenue 3-Year CAGR | 3.24% | 1.59% | 0.23% | 0.45% |
| Free Cash Flow Growth | 114.28% | 7.35% | 226.57% | -155.42% |
| Safety | ||||
| Net Debt / EBITDA | -5.12 | -6.42 | -5.19 | -4.85 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.30 | 0.30 | 0.27 | 0.27 |
| Cash Conversion Cycle | 306.17 | 310.36 | 328.85 | 321.15 |